Biosimilars Policy Roundup for July 2024—Podcast Edition

On this episode of Not So Different, we review all the big biosimilar policy news from July, including discussions regarding biosimilar policies, in both the US and abroad, as well as 3 highly anticipated FDA approvals.

Show notes

1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara

2. Ahzantive Receives FDA Approval as New Eylea Biosimilar

3. FDA Approves Epysqli as Second Soliris Biosimilar

4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed

5. Biosimilars and Employers: Strategies for Success

6. Learning the Lingo of Biologics and Biosimilars Is Critical

7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings

8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch